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The purpose of this study was to determine optimal extent of prophylactic irradiation of paraaor-
tic lymph nodes (PALN) in patients with uterine cervical cancer who hadmetastatic pelvic LNs.
Methods and Materials
We retrospectively evaluated 103 patients with cervical cancer and pelvic lymph nodemetas-
tasis who were treated with prophylactic semi-extended field radiotherapy (SEFRT) between
1990 and 2012. The semi-extended field included PALN below the second lumbar spine with
prescribed doses of 45 to 50 Gy. Survival outcomes were calculated using the Kaplan-Meier
method, and acute and late toxicities were scored using the Radiation Therapy Oncology
Group and European Organisation for Research and Treatment of Cancer toxicity criteria.
Results
The median follow-up after SEFRT was 61 (range 5–296) months. Overall, 28 patients
(27.2%) experienced treatment failures, which were classified as local in 8 patients (7.8%),
regional in 8 patients (7.8%), and distant in 13 patients (12.6%). Of the regional failures,
only two involved PALN failure around the renal artery or the renal hilum area at the upper
margin of the semi-extended field. At 5 years, the overall survival was 82%. Grade 3 or
higher acute gastrointestinal and genitourinary toxicities occurred in one and two patients,
respectively. As a late toxicity, one patient developed grade 3 small bowel obstruction.
Conclusion
Prophylactic SEFRT provided favorable outcomes with little acute or late gastrointestinal
toxicity. For prophylaxis of PALN recurrences, upper part of PALN might not need to be
included in patients with uterine cervical cancer and metastatic pelvic LNs.
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Introduction
Whole-pelvic radiotherapy used definitively with or without chemotherapy is a mainstay of
standard treatment and improves locoregional disease control and overall survival (OS) in
patients with cervical cancer [1, 2]. Metastasis to the lymph nodes (LNs) is one of the most
important prognostic factors in cervical cancer [3–5]. Uterine cervical cancer tends to be local-
ized to the pelvis and to undergo an orderly lymphatic spread to the pelvic, para-aortic, and
supraclavicular LNs [6, 7]. When the pelvic LN is involved, the incidence of common iliac and/
or para-aortic LN involvement can reach 50% [8, 9]. Even if no lymphadenopathy is found in
the para-aortic area, micrometastatic disease at the next echelon of nodes should be eradicated
as part of the management of patients with cervical cancer with pelvic LN involvement.
Extended field radiotherapy (EFRT) has been used with curative intent, either prophylacti-
cally or therapeutically, according to the involvement of the para-aortic LN (PALN). Patients
often suffer from serious toxicities, however, including gastrointestinal toxicities and especially
duodenal injury. To minimize those kinds of complications, our institutional policy for the last
two decades has been to use semi-extended field radiotherapy (SEFRT) that excludes the upper
one third of the PALN chain. The purpose of this study is to assess the clinical outcomes in
patients treated with SEFRT and determine optimal extent of prophylactic irradiation of PALN
in patients with uterine cervical cancer who had metastatic pelvic LNs.
Materials and Methods
Patient characteristics and treatment profiles
This retrospective study was approved by the Institutional Review Board of the Severance hos-
pital (IRB No. 4-2015-0059). The consent was not necessary, because patient records and infor-
mation were anonymized and de-identified prior to analysis. In this study, a total of 103
patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB to stage
IVA cervical cancer who were treated with SEFRT at Yonsei Cancer Center from 1990 to 2012
were retrospectively analyzed. All of the patients underwent a physical examination, pelvic
examination, complete blood cell counts, and chemistry profiles including liver and renal func-
tion tests as a baseline study. LN metastases were evaluated by computed tomography [10],
magnetic resonance imaging (MRI), positron emission tomography (PET), or PET-CT. LNs
larger than 1 cm in the short-axis dimension were considered to have metastatic involvement.
Additionally, we regarded central necrosis as a significant criterion for metastatic disease
within the LN [11]. For the PET or PET-CT image interpretation, a malignant lymphadenopa-
thy was defined as follows: 1) fluorodeoxyglucose accumulation in the LN greater than that in
the liver or similar to that in the brain cortex or 2) a standardized uptake value of a lesion,
which corresponded to the CT, that did not decrease on the delayed PET image compared with
that on the initial PET image [12]. None of the patients had the PALN assessed surgically.
In our institution, patients with cervical cancer received individualized RT according to pel-
vic and para-aortic nodal status as follows: whole-pelvic RT for negative LN, SEFRT to exclude
upper PALN for positive pelvic LN only, and EFRT for PALN metastasis. SEFRT was delivered
using a four-field (anterior-posterior/posterior-anterior and two lateral fields) box technique.
The superior border was the second lumbar spine (L2), and the inferior border was the obtura-
tor foramen or at least 2 cm beyond the lower extent of the disease. The lateral border of the
pelvis and the semi-extended field (SEF) encompassed areas 1.5 cm beyond the bony pelvic
rim and 1 cm lateral to the aorta or tips of transverse processes, respectively (Fig 1). In the lat-
eral view, the superior and inferior borders were identical to those of the anterior-posterior/
posterior-anterior fields. The anterior border covered the symphysis pubis and intersected the
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posterior border at the S2-S3 space. The anterior border of the SEF was 2 cm anterior to the
vertebral body surface.
We prescribed a radiation dose of 45 Gy in 25 fractions to the SEF, which is the same dose
used in EFRT. Intracavitary high-dose rate brachytherapy consisted of 30–39 Gy in 6–13 frac-
tions given two or three times per week. A midline block was added after 30.6–45 Gy during
the insertions of intracavitary brachytherapy. Sites of pelvic LN metastases received an
Fig 1. The beam’s eye view of the semi-extended radiation field using a four-field technique. (a) Anterior-Posterior, (b) Posterior-Anterior, (c) Left
lateral, and (d) Right lateral.
doi:10.1371/journal.pone.0145158.g001
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additional external boost to a median dose of 5.4 Gy (range: 5.4–18 Gy) at the discretion of the
radiation oncologists.
Assessment
Acute toxicities were evaluated at least once per week during treatment. After the completion
of treatment, all patients were evaluated every three months for the first two years and every six
months thereafter. Follow-up evaluations included a pelvic examination, cervical cytology, and
CT or MRI. Late toxicities were evaluated from six months onward after treatment, and the
development of gastrointestinal (rectum, small bowel) and urogenital symptoms was noted.
Acute and late toxicities were scored using the Radiation Therapy Oncology Group (RTOG)
and European Organisation for Research and Treatment of Cancer toxicity criteria [13].
Statistical analysis
Patterns of failure, OS, and recurrence-free survival (RFS) were evaluated. The sites of failure
were recorded as local, regional, or distant. In terms of the RT field, in-field failure was defined
as disease in the pelvic area and the PALN within the SEF, and out-field failure was defined as
disease outside the treatment field, especially in the PALN located at the superior border of L2
or higher. Survival was defined from the date of the completion of RT to the date of the last fol-
low-up or death. Time to recurrence was measured from the date of completion of RT to the
date of first failure. Survival data were analyzed using the Kaplan-Meier method. A univariate
analysis was performed using the log-rank test to identify parameters associated with the treat-
ment outcome, and multivariate analyses were performed using a Cox regression model. A p-
value 0.05 was considered statistically significant.
Results
Patient characteristics
The median patient age was 52 years (range: 28–81 years). The characteristics of the patients
are listed in Table 1. Most patients had FIGO stage IB to IIIB disease. The tumor histology was
defined as squamous cell carcinoma in 98 patients and adenocarcinoma in four patients. Sev-
enty-six patients (73.8%) received concurrent chemoradiation therapy, and 26 patients (25.2%)
were treated with radiotherapy alone.
The treatment compliance was good, and all patients completed the scheduled RT, although
there were delays of RT because of acute toxicity, mainly manifesting as hematologic problems,
in 11 patients. The median duration of overall treatment was 9.6 weeks (range: 6.4–17.7
weeks).
Treatment outcomes
The median follow-up period for surviving patients was 61 months (range: 5–296 months).
The five-year actuarial OS, RFS, local failure-free survival (LFFS), regional failure-free survival
(RFFS) and distant metastasis-free survival (DMFS) rates were 82%, 76%, 94%, 92%, and 88%,
respectively. The curves of the 5-year OS and RFS rates are shown in Fig 2. The results of the
analyses of prognostic factors are presented in Table 2. The univariate analysis showed that the
5 year RFFS was significantly different between patients with stage I–II and stage III–IV dis-
ease, respectively (97% vs. 76%, p = 0.008). The use of chemotherapy was associated with
improved 5-year DMFS (92% vs. 71%, p = 0.039; Fig 2). In case of iliac chain involvement, 5
year LFFS was higher than without it, for example, obturator nodes deep in the pelvis (96.9%
vs. 85.9%, p = 0.02).
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Ninety-five patients (92.2%) had complete remission, and eight patients (7.8%) had partial
remission after the completion of RT. No stable or persistent disease was observed in any of the
patients. During the follow-up period, 75 patients (72.8%) had no recurrence, and 28 patients
(27.2%) experienced treatment failure as follows: eight patients (7.8%) had local recurrence,
eight patients (7.8%) had regional recurrence, and 13 patients (12.6%) had distant metastasis at
the time of analysis. One patient had simultaneous regional and distant recurrence.
Of the regional failures, a total of four recurrences occurred exclusively within the SEF.
Another four recurrences were found outside of the SEF. Fig 3 shows the patterns of nodal
recurrences. PALN failures occurred in two patients (1.9%). One patient treated with SEFRT
with a superior border at the L3 level had failure in both the PALN at the renal hilum level and
the supraclavicular LN. Another patient had an isolated PALN failure at the renal artery level
after concurrent chemoradiation therapy. The characteristics of the patients who had nodal
failures are summarized in Table 3.
Table 1. Patient and tumor characteristics.
Variable Level Number of patients (%)
All patients 103 (100)
Age, yr Median (range) 52 (28–81)




Histology Squamous 98 (95.1)
Adenocarcinoma 4 (3.9)
Other 1 (1.0)
Tumor size, cm Median(range) 5 (1–9.7)
Highest nodal
involvement
Pelvic cavity 24 (23.3)
Iliac chain 79 (76.7)
EBRT dose (cGy) 4500 100 (97.1)
5040 3 (2.9)




ICR courses, fx Median (range) 6 (6–13)
Point A total dose,
cGy
Median (range) 6600 (5340–10260)






Follow-up, mo Median(range) 61 (5–296)
Abbreviations: FIGO = The International Federation of Gynecology and Obstetrics; EBRT = External Beam
Radiotherapy; LN = lymph node; ICR = Intracavitary radiotherapy.
doi:10.1371/journal.pone.0145158.t001
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Fig 2. Kaplan-Meier survival curves for the 103 patients analyzed in this study. (a) Overall Survival (OS) and Recurrence Free Survival (RFS) rates, (b)
Distant Metastasis-Free Survival (DMFS) rates for the treatment with radiotherapy (RTx) and chemotherapy (CTx) versus treatment with RT alone.
doi:10.1371/journal.pone.0145158.g002
Table 2. Effect of prognostic factors on treatment outcomes in univariate analyses.
Prognostic factor 5-yr OS 5-yr RFS 5-yr LFFS 5-yr RFFS 5-yr DMFS
% p % p % p % p % p
Age 0.14 0.446 0.217 0.687 0.856
50yr 77.5 76.4 92.4 92 90.9
>50yr 85.9 74.5 96 91.7 85.3
Tumor size 0.92 0.561 0.944 0.568 0.984
4cm 81.1 78.9 95.1 94.8 87.7
>4cm 83.4 72.9 94 89.3 88
Stage 0.415 0.118 0.342 0.008 0.441
FIGO I-II 85.3 81 96.8 96.9 86.5
FIGO III-IV 73.3 59.7 87.6 76 92.6
Chemotherapy 0.892 0.196 0.898 0.864 0.039
Yes 82.8 78.2 94 90.8 92.2
No 80.8 64.8 96 96.2 70.8
Nodal involvement 0.982 0.126 0.02 0.819 0.371
Iliac chain(+) 83 77.6 96.9 91.4 88.1
Iliac chain(-) 78.7 69.2 85.9 92.9 87.5
RT duration 0.708 0.88 0.659 0.816 0.836
9wks 86.4 76.2 97.1 92 85.6
>9wks 79.2 75.3 92.6 91.7 89.5
Abbreviations: OS = overall survival; RFS = relapse free survival; LFFS = local failure free survival; RFFS = regional failure free survival; DMFS = distant
metastasis free survival; FIGO = The International Federation of Gynecology and Obstetrics
doi:10.1371/journal.pone.0145158.t002
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Treatment-related toxicity
Most of the acute grade 3–4 toxicities were hematologic problems including anemia and neu-
tropenia. Although RT for six patients (5.8%) was delayed because of low neutrophil counts, all
of the patients were properly managed and recovered sufficiently to continue the scheduled
treatment. Acute gastrointestinal toxicity was observed in 21 patients (20.4%), of which mild
and moderate diarrhea and abdominal pain were the most common toxicities (grade 1 or 2).
One patient experienced acute grade 3 diarrhea and received treatment without RT delay. No
serious acute genitourinary toxicities were noted.
Fig 3. The patterns of nodal recurrence for seven patients. A total 10 recurrent sites are indicated along the inferior mesenteric artery (IMA), common iliac
(CI), external iliac (EI), internal iliac (II) chain, and inguinal iliac chain. Two para-aortic LN failures lie between the upper borders of the semi-extended field
(SEF) and the extended field (EF), respectively.
doi:10.1371/journal.pone.0145158.g003
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Fourteen patients (13.6%) suffered late gastrointestinal toxicities. Most of those were lower
gastrointestinal problems located entirely in the pelvic field. One patient had a grade 2 partial
small bowel obstruction, which was not surgically managed but required supportive care such
as L-tube insertion. Three patients (2.9%) experienced late grade 3 toxicities. Among those,
one patient had a small bowel obstruction that required surgical intervention at 158 months.
The patient underwent an ileostomy and segmental resection of the small intestine. Other
patients had radiation proctitis. Another patient was diagnosed with radiation proctitis but
refused any evaluations and treatments except for transfusion to treat the severe anemia caused
by 7 months of rectal bleeding. That patient expired 14 months after RT due to progressive rec-
tal bleeding. As a genitourinary toxicity, two patients experienced vesicovaginal/recto-vesicova-
ginal fistulas that required surgical management at 11 months and 12 months, respectively. No
patients experienced grade 4 or higher genitourinary toxicity.
Discussion
Cervical cancer metastasizes to the regional LNs, spreading in a contiguous manner, initially
involving the lower pelvis and then progressing to the high pelvic LNs, including the common
iliac nodes followed by the para-aortic nodes [14]. Consequently, occult metastasis or micro-
metastasis to the common iliac and/or para-aortic LNs can occur in patients with pelvic LN
involvement, and failures occur just outside the standard pelvic radiation field [15]. Those
patients may benefit from EFRT to prevent recurrence at PALN chain.
A profound understanding the flow of the PALN is crucial for determining the extent of RT
and improving patient survival, although the question of the extent of the optimal superior
border of pelvic RT remains unresolved. Given the anatomy of lymphatic drainage, the right
and left lumbar trunks formed by the union of the efferent vessels from the lateral aortic lymph
glands receive the lymph from the common iliac chains, ovaries, uterine tubes, and body of the
uterus. Ultimately, the lumbar trunks empty into the cisterna chyli, a dilated sac at the begin-
ning of the thoracic duct that drains into the left subclavian vein [16, 17]. Therefore, the cis-
terna chyli located at the level of L2 seems to play an important role as a sort of station for
systemic metastasis through the PALNs. Clinicopathological studies also provide a rationale
for setting the superior border of the SEF at the L2 level [18]. On determining the surgical stag-
ing extent of the PALNs, some gynecological oncologists consider the origin of the inferior
mesenteric artery (IMA) as the upper dissection margin based on the finding that PALN
Table 3. Characteristics of patients with nodal failure.
No Age Stage RTx (EBRT+ LN
boost)




1 79 IIIA 45Gy+5.4Gy None Rt.external iliac Both external iliac,
inguinal
5 L2
2 47 IIIB 45Gy+5.4Gy Concurrent Rt.external iliac Lt. common iliac 11 L2
3 50 IIB 45Gy+9Gy Concurrent Rt.external iliac Both common iliac 14 L2
4 41 IIB 45Gy+5.4Gy Concurrent Both external iliac and internal
iliac
Both common iliac 16 L3
5 62 IIIB 45Gy+5.4Gy Concurrent Lt. external iliac Rt.inguinal 9 L2
6 43 IIB 45Gy+none None Lt. obturator Paraaortic (Renal
hilum)
67 L3
7 63 IVA 45Gy+9Gy Concurrent Both hypogastric area Paraaortic (Renal
artery)
39 L2
Abbreviations: RTx = radiotherapy; EBRT = external beam radiotherapy; CTx = chemotherapy; LN = lymph node; SEF = semi-extended ﬁeld
doi:10.1371/journal.pone.0145158.t003
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metastases above the IMA hardly occur in the absence of node metastasis below the IMA.
According to a review of 733 complete infrarenal lymphadenectomies, 54 patients (54/207,
26.08%) had PALNmetastasis with pelvic node metastasis. Of those with PALN metastasis,
only 10 patients (1.36%) were found to have LN metastasis above the level of the IMA without
node metastasis in the lower part of the para-aortic area [19]. Therefore, for patients who are
positive only in the pelvic node, prophylactic irradiation to prevent PALN recurrence might be
enough to cover the cisterna chyli and the level of the IMA up to L2.
Detailed patterns of regional failure can help determine extent of the radiation field.
Researchers at the M.D. Anderson Cancer Center analyzed the relationship between recurrence
and the radiation field and showed that the most common site of regional recurrence was mar-
ginal, usually just above the superior boundary of the RT field [20]. Of the 198 patients who
had a regional recurrence after definitive RT for cervical cancer, 103 (52%) were treated with
pelvic RT with a superior field border at L4/5, while 7 (3.5%) were treated with pelvic RT with
a superior field border at L2/3. Of the 180 patients who had an evaluable regional recurrence,
119 (66%) had a component of marginal failure, indicating that the proportion of nodal recur-
rence may be higher with a smaller field. Thus, the study at M.D. Anderson provided strong
support for our institutional practice of setting the upper border of the EF at the L2 spine level
if bowel sparing could be established.
Several previous studies showed that patients with pelvic LN involvement were effectively
treated with EFRT but that treatment-related toxicity was relatively severe. A prospective ran-
domized study demonstrated that prophylactic EFRT with elective para-aortic irradiation
improved survival and reduced distant metastases compared with pelvic-only irradiation [21].
The cumulative incidence of grade 4–5 toxicities after 10 years in the EFRT arm was 8% com-
pared with 4% in the pelvic-only arm. Extending the radiation field to the para-aortic region
increased the irradiated dose to the small bowel, especially the duodenum. In addition, a previ-
ous analysis showed EFRT to be a significant predictor of severity and chronicity of ongoing
disease in patients who live with radiation-induced bowel injury after treatment for cervical
cancer [22]. In this study, we hypothesized that using SEFRT to exclude the upper PALNs
could reduce toxicities, especially upper gastrointestinal toxicities, without compromising
treatment outcomes. Among the four patients who experienced grade 3 or higher gastrointesti-
nal toxicity, only one experienced small bowel obstruction requiring surgical intervention.
That encouraging finding supports the hypothesis that SEFRT might be considered for reduc-
ing upper gastrointestinal toxicities, although there has been no prospective clinical trial to
evaluate the efficacy of SEFRT compared with that of EFRT until now.
SEFRT also showed favorable PALN control and survival outcomes. When the profiles of
nodal failures were analyzed according to the radiation field, only two patients (1.9%) experi-
enced out-field PALN failures between the respective upper borders of SEFRT and EFRT.
Other failures were classified as in-field failures or distant nodal failures. The five-year OS rate
in the EFRT arms was 67% and 52% in RTOG trial 79–20 and RTOG trial 90–01, respectively
[21, 23]. Recent institutional series showed 5 year OS rates of 73.5% and 72.4%, respectively
[24, 25]. The 5 year survival rate in our study was superior to those in the previous studies, sug-
gesting that SEFRT excluding the upper PALN does not significantly compromise PALN con-
trol, survival outcomes, and toxicities compared with EFRT.
Intensity-modulated radiotherapy (IMRT) has been considered a promising modality to
reduce toxicity and improve effective nodal control and treatment outcomes. A recent study
reported that IMRT may allow sufficient dose sparing of the small bowel and was associated
with no duodenal-specific toxicity for the treatment of the para-aortic nodes. The study
reported on the clinical outcomes for 32 patients treated with prophylactic EF-IMRT [26]. The
3 year actuarial OS was 87% and only one patient experienced late grade 3 gastrointestinal
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complication. Because EF-IMRT was shown to be a safe and effective modality, SEF-IMRT is
expected to have less toxicity with comparable treatment outcomes.
Our findings must be interpreted with caution because of several drawbacks. Because this
study was a retrospective study covering over 20 years, heterogeneity among the patient char-
acteristics might have confounded the results. The most important issue is how to evaluate
metastasis of the pelvic and para-aortic LNs, which were determined not by laparotomy but by
various imaging modalities including CT, MRI, PET, and PET-CT over a long period.
In conclusion, our results suggest that prophylactic SEFRT in patients with uterine cervical
cancer and metastasis in the pelvic LNs without PALN involvement provided favorable treat-
ment outcomes with acceptable acute and late gastrointestinal toxicities comparable to those of
EFRT. Therefore upper part of PALN might not need to be included in patients with uterine
cervical cancer and metastatic pelvic LNs for prophylaxis of PALN recurrences.
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